Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001662774-25-000032
Filing Date
2025-05-13
Accepted
2025-05-13 08:40:57
Documents
90
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q qncx-20250331.htm   iXBRL 10-Q 1002198
2 EX-31.1 qncx-2025331xexx311.htm EX-31.1 10012
3 EX-31.2 qncx-2025331xexx312.htm EX-31.2 10247
4 EX-32.1 qncx-2025331xexx321.htm EX-32.1 6812
5 EX-32.2 qncx-2025331xexx322.htm EX-32.2 6850
  Complete submission text file 0001662774-25-000032.txt   7148031

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20250331.xsd EX-101.SCH 54846
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT qncx-20250331_cal.xml EX-101.CAL 81885
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT qncx-20250331_def.xml EX-101.DEF 274100
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20250331_lab.xml EX-101.LAB 664661
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20250331_pre.xml EX-101.PRE 506047
92 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20250331_htm.xml XML 996212
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38890 | Film No.: 25937387
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)